BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1119@pharmaconomics
DTSTAMP:20260707T021638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:DTIL Phase 3 — PBGENE-DMD (estimated date)
DESCRIPTION:Phase 3 trial results for PBGENE-DMD in Duchenne Muscular Dystrophy are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/a20260112jpmrelease.htm\n\nTrack it: https://pharmaconomics.com/e/1119
URL:https://pharmaconomics.com/e/1119
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DTIL catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR